John Daniel Hainsworth
Sarah Cannon · 755 works · 57,475 citations · h-index 98
Top works
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
- Adjuvant Docetaxel for Node-Positive Breast Cancer
- Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer
- Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
- Diagnostic and therapeutic management of cancer of an unknown primary
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
- Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
- Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma
- Treatment of Patients with Cancer of an Unknown Primary Site
- Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer.
- Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
- Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma
- A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
- Poorly Differentiated Neuroendocrine Carcinoma of Unknown Primary Site